Bristol-Myers Squibb Company vs Telix Pharmaceuticals Limited: Annual Revenue Growth Compared

Pharma Giants vs. Innovators: Revenue Growth Battle

__timestampBristol-Myers Squibb CompanyTelix Pharmaceuticals Limited
Wednesday, January 1, 20141587900000028336824
Thursday, January 1, 20151656000000032319194
Friday, January 1, 20161942700000029404631
Sunday, January 1, 20172077600000031769230
Monday, January 1, 20182256100000020439380
Tuesday, January 1, 20192614500000024186536
Wednesday, January 1, 2020425180000004680000
Friday, January 1, 2021463850000004898000
Saturday, January 1, 202246159000000155984000
Sunday, January 1, 202345006000000496659000
Monday, January 1, 202448300000000
Loading chart...

Infusing magic into the data realm

A Tale of Two Companies: Revenue Growth from 2014 to 2023

In the dynamic world of pharmaceuticals, Bristol-Myers Squibb Company and Telix Pharmaceuticals Limited have charted distinct paths over the past decade. Bristol-Myers Squibb, a titan in the industry, has seen its revenue grow by approximately 183% from 2014 to 2023, peaking in 2021. This growth underscores its robust market presence and strategic acquisitions. In contrast, Telix Pharmaceuticals, a rising star, has experienced an explosive growth of over 1,600% in the same period, reflecting its innovative approach and expanding product pipeline.

While Bristol-Myers Squibb's revenue surged significantly in 2020, Telix's revenue saw a remarkable jump in 2022, highlighting its breakthrough developments. This comparison not only showcases the diverse strategies of established and emerging players but also offers insights into the evolving landscape of the pharmaceutical industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025